Positive News Sentiment NASDAQ:DCPH Deciphera Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $13.26 +0.11 (+0.84%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$12.76▼$13.4150-Day Range$9.11▼$13.9852-Week Range$6.51▼$14.48Volume56,568 shsAverage Volume1.16 million shsMarket Capitalization$878.08 millionP/E RatioN/ADividend YieldN/APrice Target$26.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Deciphera Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.11 Rating ScoreUpside/Downside100.4% Upside$26.57 Price TargetShort InterestBearish15.61% of Float Sold ShortDividend StrengthN/ASustainability-1.66Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$14.79 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.62) to ($1.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.47 out of 5 starsMedical Sector108th out of 1,428 stocksPharmaceutical Preparations Industry35th out of 680 stocks 3.1 Analyst's Opinion Consensus RatingDeciphera Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 3 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.57, Deciphera Pharmaceuticals has a forecasted upside of 100.4% from its current price of $13.26.Amount of Analyst CoverageDeciphera Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.61% of the float of Deciphera Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDeciphera Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Deciphera Pharmaceuticals has recently increased by 7.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDeciphera Pharmaceuticals does not currently pay a dividend.Dividend GrowthDeciphera Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDeciphera Pharmaceuticals has received a 59.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ripretinib", "Clinical research services for cancer", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Deciphera Pharmaceuticals is -1.66. Previous Next 3.8 News and Social Media Coverage News SentimentDeciphera Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Deciphera Pharmaceuticals this week, compared to 1 article on an average week.Search Interest21 people have searched for DCPH on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows4 people have added Deciphera Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Deciphera Pharmaceuticals insiders have bought 44,771.91% more of their company's stock than they have sold. Specifically, they have bought $14,789,780.00 in company stock and sold $32,960.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Deciphera Pharmaceuticals is held by insiders.Percentage Held by Institutions87.97% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.62) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Deciphera Pharmaceuticals is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Deciphera Pharmaceuticals is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDeciphera Pharmaceuticals has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Deciphera Pharmaceuticals (NASDAQ:DCPH) StockDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Read More DCPH Stock News HeadlinesJune 24, 2022 | americanbankingnews.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 52-Week High at $13.05June 23, 2022 | americanbankingnews.comMatthew L. Sherman Sells 1,768 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) StockJuly 5, 2022 | Investing Trends (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Stock In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...June 22, 2022 | americanbankingnews.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Insider Jama Pitman Sells 1,298 Shares of StockJune 10, 2022 | americanbankingnews.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 12-Month High at $12.21June 3, 2022 | seekingalpha.comBlueprint Medicines, Deciphera, Black Diamond gain following Turning Point sale to Bristol MyersJune 2, 2022 | finance.yahoo.comDeciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor ConferencesMay 11, 2022 | finance.yahoo.comWe Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth CarefullyJuly 5, 2022 | RJO Futures (Ad)A One Stop Shop for Everything Futures TradingWhether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets! May 5, 2022 | finance.yahoo.comAmarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa GenericsMay 4, 2022 | ca.investing.comDeciphera Pharmaceuticals Tops Q1 EPS by 10cMay 4, 2022 | finance.yahoo.comDeciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial ResultsMay 3, 2022 | benzinga.comPreview: Deciphera Pharmaceuticals's EarningsMay 2, 2022 | finance.yahoo.comDeciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022April 29, 2022 | finance.yahoo.comDeciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesApril 28, 2022 | finance.yahoo.comBioMarin (BMRN) Q1 Earnings and Revenues Beat EstimatesApril 28, 2022 | finance.yahoo.comEli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock RisesApril 26, 2022 | seekingalpha.comBanco Santander, Polaris, Redfin among premarket losers' packApril 15, 2022 | finance.yahoo.comWall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 73%: Read This Before Placing a BetMarch 10, 2022 | msn.comDeciphera Pharmaceuticals, Inc. (DCPH) Down 15% Since Last Earnings Report: Can It Rebound?February 7, 2022 | finance.yahoo.comDrug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPHFebruary 1, 2022 | finance.yahoo.comAnalysts Estimate Deciphera Pharmaceuticals, Inc. (DCPH) to Report a Decline in Earnings: What to Look Out forFebruary 1, 2022 | finance.yahoo.comDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022January 24, 2022 | finance.yahoo.comDeciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series SessionJanuary 3, 2022 | finance.yahoo.comDeciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare ConferenceDecember 30, 2021 | fool.comDeciphera Pharmaceuticals, Inc.(DCPH)December 1, 2021 | finance.yahoo.comDeciphera Pharmaceuticals lays off more than a third of its staffSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCPH CUSIPN/A CIK1654151 Webwww.deciphera.com Phone(781) 209-6400FaxN/AEmployees280Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today7/05/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$26.57 High Stock Price Forecast$70.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+100.4%Consensus RatingHold Rating Score (0-4)2.11111111111111 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($4.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-299,960,000.00 Net Margins-279.96% Pretax Margin-284.95% Return on Equity-79.96% Return on Assets-61.03% Debt Debt-to-Equity RatioN/A Current Ratio3.69 Quick Ratio3.46 Sales & Book Value Annual Sales$96.15 million Price / Sales9.13 Cash FlowN/A Price / Cash FlowN/A Book Value$5.21 per share Price / Book2.55Miscellaneous Outstanding Shares66,220,000Free Float63,502,000Market Cap$878.08 million OptionableOptionable Beta1.19 Deciphera Pharmaceuticals Frequently Asked Questions Should I buy or sell Deciphera Pharmaceuticals stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Deciphera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares. View analyst ratings for Deciphera Pharmaceuticals or view top-rated stocks. What is Deciphera Pharmaceuticals' stock price forecast for 2022? 9 brokerages have issued 1 year target prices for Deciphera Pharmaceuticals' stock. Their DCPH stock forecasts range from $6.00 to $70.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $26.57 in the next twelve months. This suggests a possible upside of 100.4% from the stock's current price. View analysts' price targets for Deciphera Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Deciphera Pharmaceuticals' stock price performed in 2022? Deciphera Pharmaceuticals' stock was trading at $9.77 at the beginning of 2022. Since then, DCPH stock has increased by 35.7% and is now trading at $13.26. View the best growth stocks for 2022 here. When is Deciphera Pharmaceuticals' next earnings date? Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Deciphera Pharmaceuticals. How were Deciphera Pharmaceuticals' earnings last quarter? Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced its earnings results on Wednesday, May, 4th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.03. The company earned $29.22 million during the quarter, compared to analysts' expectations of $27.17 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 79.96% and a negative net margin of 279.96%. The company's quarterly revenue was up 16.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.06) EPS. View Deciphera Pharmaceuticals' earnings history. Who are Deciphera Pharmaceuticals' key executives? Deciphera Pharmaceuticals' management team includes the following people: Mr. Steven L. Hoerter, Pres, CEO & Director (Age 51, Pay $1.01M)Dr. Daniel L. Flynn Ph.D., Exec. VP, Chief Scientific Officer & Founder (Age 67, Pay $645.61k)Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 51, Pay $644.12k) (LinkedIn Profile)Mr. Daniel C. Martin, Sr. VP & Chief Commercial Officer (Age 47, Pay $611.24k)Dr. Matthew L. Sherman M.D., Exec. VP & Chief Medical Officer (Age 66, Pay $725.85k)Dr. Stephen B. Ruddy Ph.D., Sr. VP & Chief Technical Officer (Age 58)Ms. Jennifer Robinson, VP of Investor RelationsMr. Jeffrey M. Held J.D., Sr. VP & Gen. CounselMs. Jama Pitman, Sr. VP of Regulatory, Quality & Portfolio Management (Age 43)Ms. Margarida Duarte, Sr. VP & Head of International What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO? 3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Deciphera Pharmaceuticals' key competitors? Some companies that are related to Deciphera Pharmaceuticals include Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), Roivant Sciences (ROIV), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Blueprint Medicines (BPMC), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), CureVac (CVAC), Indivior (INVVY), Pacira BioSciences (PCRX), Insmed (INSM) and HUTCHMED (HCM). View all of DCPH's competitors. What other stocks do shareholders of Deciphera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL). When did Deciphera Pharmaceuticals IPO? (DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers. What is Deciphera Pharmaceuticals' stock symbol? Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH." How do I buy shares of Deciphera Pharmaceuticals? Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Deciphera Pharmaceuticals' stock price today? One share of DCPH stock can currently be purchased for approximately $13.26. How much money does Deciphera Pharmaceuticals make? Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $878.08 million and generates $96.15 million in revenue each year. The company earns $-299,960,000.00 in net income (profit) each year or ($4.89) on an earnings per share basis. How many employees does Deciphera Pharmaceuticals have? Deciphera Pharmaceuticals employs 280 workers across the globe. How can I contact Deciphera Pharmaceuticals? Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for Deciphera Pharmaceuticals is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com. This page (NASDAQ:DCPH) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
